Monitoring and evaluation of the efficacy and safety of Artesunate-Mefloquine (ASMQ) and Artesunate-Pyronaridine (ASP) for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Cambodia

Phase 2

• Conditions: Patients with Plasmodium falciparum infection; Patients with Plasmodium vivax infection; Infection - Other infectious diseases

• Registration Number: ACTRN12622000638730
• Lead Sponsor: Ministry of Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-12-31
• Study Start: 2022-05-02
• Last Update Posted: 9 May 2022

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

The study population consisted of patients with uncomplicated P. falciparum or P. vivax malaria attending the study health clinic who are aged between 2-60 years for ASP and 18-60 years for ASMQ. All adult patients were above 18 years, age of majority in this country, signed an informed consent form for participation. Parents or guardians were informed consent on behalf of children who have not reached the age of majority. Children aged from 12 years and age of majority are required to consent for participation by signing an informed assent form.

Exclusion Criteria

- Pregnancy or lactation
- Severe malaria
- Mixed malaria infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified